Patents by Inventor Rubi Burlage

Rubi Burlage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11096890
    Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 24, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wycliffe S. Omwancha, Rubi Burlage
  • Publication number: 20200262922
    Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Soumendu Bhattacharya, Chakravarthy Nachu Narasimhan, Manoj K. Sharma, Xiaoyu Yang, Arnab De, Rubi Burlage, Jason K. Cheung
  • Publication number: 20200055938
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava
  • Publication number: 20190099368
    Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof, fully or partially pregelatinized starch, a texture-modifying gum, a lubricant, an emulsifier, a flavoring agent, and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
    Type: Application
    Filed: September 25, 2018
    Publication date: April 4, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wycliffe S. Omwancha, Rubi Burlage
  • Publication number: 20190099367
    Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
    Type: Application
    Filed: September 25, 2018
    Publication date: April 4, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wycliffe S. Omwancha, Rubi Burlage
  • Patent number: 9833463
    Abstract: The present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: December 5, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wycliffe Omwancha, Rubi Burlage
  • Publication number: 20170042922
    Abstract: The present invention provides for a sitagliptin tannate complex or a pharmaceutical compositions or a pharmaceutically acceptable intermediates comprising said complex. This invention also relates to a processes to prepare the sitagliptin tannate complex as well as to methods of using the sitagliptin tannate complex to treat diabetes, obesity and high blood pressure.
    Type: Application
    Filed: April 13, 2015
    Publication date: February 16, 2017
    Inventors: Wycliffe Omwancha, Rubi Burlage
  • Publication number: 20120141586
    Abstract: The present invention provides for a pharmaceutical formulation which comprises a) a compound of the formula (I): SCH 530348 or the bisulfate salt thereof; b) clopidogrel; and c) silicified microcrystalline cellulose.
    Type: Application
    Filed: June 7, 2010
    Publication date: June 7, 2012
    Inventors: Rubi Burlage, Abdul S. Gafur, Srinivas S. Duggirala